Stock Scorecard
Stock Summary for Ligand Pharmaceuticals Inc - Class B (LGND) - $105.89 as of 10/17/2024 9:16:43 PM EST
Total Score
16 out of 30
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for LGND
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LGND
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LGND
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LGND
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for LGND
Financial Details for LGND
Company Overview |
|
|---|---|
| Ticker | LGND |
| Company Name | Ligand Pharmaceuticals Inc - Class B |
| Country | USA |
| Description | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 6/30/2024 |
| Next Earnings Date | 11/6/2024 |
Stock Price History |
|
| Last Day Price | 105.89 |
| Last Day Price Updated | 10/17/2024 9:16:43 PM EST |
| Last Day Volume | 72,951 |
| Average Daily Volume | 88,211 |
| 52-Week High | 112.13 |
| 52-Week Low | 49.24 |
| Last Price to 52 Week Low | 115.05% |
Valuation Measures |
|
| Trailing PE | 44.80 |
| Industry PE | 38.31 |
| Sector PE | 81.65 |
| 5-Year Average PE | 22.35 |
| Free Cash Flow Ratio | 8.53 |
| Industry Free Cash Flow Ratio | 13.51 |
| Sector Free Cash Flow Ratio | 33.70 |
| Current Ratio Most Recent Quarter | 16.82 |
| Total Cash Per Share | 12.42 |
| Book Value Per Share Most Recent Quarter | 42.82 |
| Price to Book Ratio | 2.44 |
| Industry Price to Book Ratio | 6.01 |
| Sector Price to Book Ratio | 22.16 |
| Price to Sales Ratio Twelve Trailing Months | 14.29 |
| Industry Price to Sales Ratio Twelve Trailing Months | 7.51 |
| Sector Price to Sales Ratio Twelve Trailing Months | 6.39 |
Share Statistics |
|
| Total Shares Outstanding | 18,269,000 |
| Market Capitalization | 1,934,504,410 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 7/2/2010 |
| Last Dividend Amount | 15.00 |
| Current Dividend Amount | 0.46 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | -96.96% |
| 3-Year Dividend Growth Rate Percentage | -96.96% |
| 5-Year Dividend Growth Rate Percentage | -96.96% |
| All-Time Dividend Growth Rate Percentage | -96.96% |
| Dividend Payout Ratio | 0.00% |
Income Statement |
|
| Quarterly Earnings Growth YOY | 103.20% |
| Annual Earnings Growth | 256.33% |
| Reported EPS 12 Trailing Months | 2.33 |
| Reported EPS Past Year | 2.60 |
| Reported EPS Prior Year | 6.10 |
| Net Income Twelve Trailing Months | 42,143,000 |
| Net Income Past Year | 52,154,000 |
| Net Income Prior Year | -33,361,000 |
| Quarterly Revenue Growth YOY | 57.50% |
| 5-Year Revenue Growth | -8.31% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 226,932,000 |
| Total Cash Past Year | 170,309,000 |
| Total Cash Prior Year | 211,870,000 |
| Net Cash Position Most Recent Quarter | 150,142,000 |
| Net Cash Position Past Year | 93,614,000 |
| Long Term Debt Past Year | 76,695,000 |
| Long Term Debt Prior Year | 76,695,000 |
| Total Debt Most Recent Quarter | 76,790,000 |
| Equity to Debt Ratio Past Year | 0.90 |
| Equity to Debt Ratio Most Recent Quarter | 0.91 |
| Total Stockholder Equity Past Year | 700,913,000 |
| Total Stockholder Equity Prior Year | 597,485,000 |
| Total Stockholder Equity Most Recent Quarter | 775,198,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 46,340,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 2.54 |
| Free Cash Flow Past Year | 46,056,000 |
| Free Cash Flow Prior Year | 119,927,000 |
Options |
|
| Put/Call Ratio | 0.48 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.01 |
| MACD Signal | -0.15 |
| 20-Day Bollinger Lower Band | 77.42 |
| 20-Day Bollinger Middle Band | 96.21 |
| 20-Day Bollinger Upper Band | 114.99 |
| Beta | 0.91 |
| RSI | 49.92 |
| 50-Day SMA | 80.51 |
| 150-Day SMA | 84.77 |
| 200-Day SMA | 97.49 |
System |
|
| Modified | 10/17/2024 5:51:22 AM EST |